...to Wyeth-Ayerst by IPIC. Servier withdrew both dexfenfluramine from the market in Europe as well. Wyeth-Ayerst...
...Laboratory at the school. Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Les Laboratoires Servier, Paris, France Wyeth-Ayerst Laboratories...

...Redux dexfenfluramine for obesity. Last month, IPIC and partner Wyeth-Ayerst Laboratories (Radnor, Penn.) withdrew Redux and Wyeth-Ayerst's...

...company on medical and scientific issues relating to the possible heart valve defects associated with Wyeth-Ayerst's...
...Laboratory at Harvard University Medical School. Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Wyeth-Ayerst Laboratories, Philadelphia, Penn. Wyeth-Ayerst...
...company on medical and scientific issues relating to the possible heart valve defects associated with Wyeth-Ayerst's...

...Redux dexfenfluramine, an isomer of fenfluramine marketed by Wyeth-Ayerst. Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Wyeth-Ayerst Laboratories...

...The partners expanded their distribution agreement for LIPO's Abelcet liposomal amphotericin B. Wyeth-Ayerst will market the...
...Wyeth-Ayerst currently markets Abelcet in France and Italy. The Liposome Co. Inc. (LIPO), Princeton, N.J. Wyeth-Ayerst...

...case outright. That decision was largely based on a similar case from 2004, Garcia v. Wyeth-Ayerst Laboratories...

...became Rotarix. Meanwhile, work had been underway for some time at NIH on rhesus-based vaccines. Wyeth-Ayerst Laboratories...
...with the approximately 7,000 children, including 2,000 randomized to receive vaccine, in the dataset that Wyeth-Ayerst...

...as VP of business development and licensing, formerly assistant VP of technology licensing of Wyeth's Wyeth-Ayerst Laboratories...

...business unit at MOG Group Hired: Hank Agersborg as CSO, formerly president of the Wyeth's Wyeth-Ayerst...

...imatinib Ph+ CML 12/20/02 Novartis 1 (1,106) Mylotarg gemtuzumab ozogamicin Acute myeloid leukemia (AML) 5/17/00 Wyeth-Ayerst...